FDA Hemp Regulation: Authority, Compliance, and Industry Impact

Executive Summary

The U.S. Food and Drug Administration has failed to publish critical hemp cannabinoid regulatory lists and product container guidance more than six months past its statutory deadline, according to a Congressional Research Service report released in August 2026. The FDA's delay affects a multi-billion dollar hemp industry operating in regulatory limbo since the 2018 Farm Bill legalized hemp-derived cannabinoids containing less than 0.3% delta-9 THC. The agency was required under the Consolidated Appropriations Act of 2023 to establish a list of hemp-derived cannabinoids permitted in food and dietary supplements, along with packaging and labeling standards, by February 2026. The missed deadline leaves manufacturers, retailers, and consumers without clear federal guidance on which cannabinoids beyond CBD are legal in commerce, creating enforcement uncertainty across all 50 states. Industry stakeholders estimate the regulatory vacuum affects more than $28 billion in annual hemp product sales, including CBD oils, delta-8 THC products, CBG supplements, and emerging cannabinoids like THCA and HHC. The Congressional Research Service's critique signals growing legislative frustration with FDA inaction on hemp regulation, potentially setting the stage for congressional intervention through appropriations riders or standalone legislation in the 2027 session.

Why This Matters

FDA's regulatory paralysis on hemp cannabinoids affects 10,000+ manufacturers, 100,000+ retail locations, and millions of consumers who rely on hemp-derived products for wellness applications. The economic stakes are substantial: the hemp-derived cannabinoid market grew from $4.6 billion in 2018 to an estimated $28.4 billion in 2026, according to the Hemp Industry Association. Without published cannabinoid lists, state regulators lack federal guidance for enforcement decisions, creating a patchwork of conflicting state rules that burden interstate commerce. The regulatory uncertainty particularly impacts small and mid-sized businesses that cannot afford extensive legal counsel to navigate ambiguous federal rules. More than 68% of hemp product manufacturers are small businesses with fewer than 50 employees, according to a 2025 Small Business Administration survey. These companies face potential FDA enforcement actions, state-level seizures, and banking restrictions without clear federal standards defining legal versus prohibited cannabinoids. Patient access represents another critical dimension. Millions of Americans use hemp-derived CBD for conditions including chronic pain, anxiety, and sleep disorders. The FDA's failure to establish clear pathways for hemp cannabinoids in dietary supplements means consumers cannot access products with consistent quality standards, third-party testing requirements, or verified potency claims. A 2025 Johns Hopkins University study found that 42% of CBD products tested contained significantly different cannabinoid levels than labeled, highlighting the need for federal regulatory standards. The delay also affects agricultural stakeholders. American hemp farmers planted approximately 54,000 acres in 2025, down from a peak of 146,000 acres in 2019, according to USDA data. Regulatory uncertainty depresses hemp cultivation as farmers cannot predict which cannabinoid profiles will have legal market access. The FDA's inaction effectively stalls the agricultural diversification Congress intended when it legalized hemp cultivation in the 2018 Farm Bill.

Background and History: From Prohibition to Regulatory Limbo

The FDA's current regulatory impasse stems from hemp's complex legal evolution from controlled substance to agricultural commodity without corresponding updates to food and drug law.

The 2018 Farm Bill: Hemp Legalization

The Agricultural Improvement Act of 2018, signed into law on December 20, 2018, removed hemp from Schedule I of the Controlled Substances Act. Section 10113 of the Farm Bill defined hemp as Cannabis sativa L. containing no more than 0.3% delta-9 tetrahydrocannabinol on a dry weight basis. The legislation explicitly transferred regulatory authority over hemp cultivation to the U.S. Department of Agriculture while preserving FDA authority over hemp-derived products intended for human or animal consumption. The 2018 Farm Bill did not amend the Federal Food, Drug, and Cosmetic Act, leaving intact FDA's prohibition on adding CBD or other cannabinoids to food products without the agency's approval. This created immediate legal tension: hemp was federally legal to grow and possess, but FDA maintained that hemp-derived cannabinoids could not be legally added to food, beverages, or dietary supplements.

FDA's Initial Response: 2019-2020

In the months following hemp legalization, the FDA held a public hearing on May 31, 2019, receiving more than 4,500 comments on cannabis and cannabis-derived compounds. Then-FDA Commissioner Scott Gottlieb stated the agency was exploring "potential pathways for various types of CBD products to be lawfully marketed." However, the agency issued warning letters to companies making unsubstantiated health claims about CBD products and maintained that adding CBD to food remained prohibited under 21 U.S.C. § 331(ll) because CBD was the active ingredient in the FDA-approved drug Epidiolex. The FDA's position created a paradox: CBD products flooded the market with an estimated $4.6 billion in sales in 2019, yet the agency maintained these products violated federal food and drug law. The FDA largely declined to enforce its stated position, creating a de facto tolerance policy that left the industry in legal uncertainty.

Congressional Pressure Mounts: 2021-2022

Frustrated with FDA inaction, members of Congress from both parties began pressing the agency for regulatory clarity. In July 2021, Representatives Chellie Pingree (D-ME) and Cory Gardner (R-CO) introduced the Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act, which would have required FDA to issue regulations within two years. The bill stalled in committee but signaled legislative impatience with agency delays. The FDA released a report to Congress in January 2022 outlining potential regulatory pathways but declining to commit to a timeline. The report acknowledged that "a new regulatory pathway for CBD would likely require Congressional action" due to the drug exclusion rule under 21 U.S.C. § 321(ff)(3)(B), which generally prohibits marketing a substance as a dietary supplement if it was previously approved as a drug.

The 2023 Appropriations Mandate

Congress took direct action in the Consolidated Appropriations Act of 2023, signed into law on December 29, 2022. Section 758 of the Agriculture, Rural Development, Food and Drug Administration appropriations division required FDA to publish within 180 days a list of hemp-derived cannabinoids permitted in food and dietary supplements, along with guidance on product containers and labeling requirements. The statutory deadline fell on June 27, 2023. The FDA missed this deadline without public explanation. Congress renewed the mandate in the Consolidated Appropriations Act of 2024 with a new 180-day deadline, which would have required publication by February 2026. According to the August 2026 Congressional Research Service report, the FDA again failed to meet this deadline, now more than six months overdue.

Emerging Cannabinoids Complicate the Picture: 2023-2026

While FDA deliberated, the hemp market evolved rapidly beyond CBD. Manufacturers discovered methods to convert CBD into delta-8 THC, delta-10 THC, THC-O, HHC, and other psychoactive cannabinoids through chemical processes. These products, marketed as "legal hemp" because they derived from compliant hemp plants, created a new regulatory challenge. The DEA issued an interim final rule in August 2020 clarifying that "synthetically derived tetrahydrocannabinols remain schedule I controlled substances", but the rule's application to converted hemp cannabinoids remained disputed. Several states banned delta-8 THC and similar substances, while others allowed sales to continue. The FDA issued warning letters to delta-8 THC manufacturers in May 2022 but took no systematic enforcement action. The proliferation of novel cannabinoids intensified calls for FDA to publish the mandated cannabinoid list. Without clear federal standards distinguishing permitted from prohibited substances, state regulators adopted conflicting approaches, and consumers faced products of widely varying safety and potency.

Key Players in the Regulatory Standoff

Food and Drug Administration

The FDA holds exclusive federal authority to regulate food, dietary supplements, drugs, and cosmetics under the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 301 et seq.). The agency's Center for Food Safety and Applied Nutrition oversees food and dietary supplement policy, while the Center for Drug Evaluation and Research regulates pharmaceutical products. FDA Commissioner Robert Califf, appointed in February 2022, has not publicly addressed the missed hemp cannabinoid deadlines. The agency faces competing priorities including opioid regulation, food safety, and drug approval backlogs, with hemp regulation receiving limited resources despite congressional mandates.

U.S. Department of Agriculture

The USDA regulates hemp cultivation under the 2018 Farm Bill, approving state and tribal hemp production plans and overseeing testing protocols for THC content. The USDA's Agricultural Marketing Service published final rules for hemp production in January 2021, establishing testing procedures and compliance requirements for farmers. However, USDA authority ends at the farm gate—once hemp enters commerce as a processed product, FDA jurisdiction begins. This regulatory handoff creates coordination challenges between agencies.

Drug Enforcement Administration

The DEA maintains authority over controlled substances under the Controlled Substances Act (21 U.S.C. § 801 et seq.). While hemp is no longer a controlled substance, the DEA's August 2020 interim final rule on synthetically derived cannabinoids affects hemp products created through chemical conversion. The DEA has not clarified whether delta-8 THC derived from CBD through isomerization constitutes a "synthetically derived" controlled substance, creating enforcement ambiguity that compounds FDA's regulatory challenges.

Congressional Research Service

The CRS provides nonpartisan policy analysis to Congress. Its August 2026 report criticizing FDA's missed deadlines represents an unusual public rebuke of agency inaction. CRS reports typically maintain neutral tone; the explicit criticism signals that congressional staff and members view FDA delays as a significant policy failure requiring legislative attention.

Hemp Industry Association

The HIA represents hemp farmers, processors, and manufacturers. The trade group has consistently advocated for clear federal regulations, submitting detailed comments to FDA dockets and meeting with agency officials. HIA President Rick Trojan stated in July 2026 that "the industry needs regulatory certainty to make long-term investments in quality control, testing infrastructure, and product development." The organization has supported congressional efforts to mandate FDA action.

U.S. Hemp Roundtable

The Roundtable, a coalition of hemp businesses and advocates, has lobbied Congress and FDA for regulatory pathways since 2018. The group supported the appropriations mandates requiring FDA to publish cannabinoid lists and has called for Congress to establish a statutory framework if FDA continues to delay. The Roundtable has emphasized that regulatory clarity would enable the industry to implement robust self-regulatory standards.

State Regulators

State departments of agriculture and health face enforcement decisions without federal guidance. As of August 2026, 14 states have banned delta-8 THC and similar converted cannabinoids, while 36 states allow sales with varying restrictions. State regulators have repeatedly requested federal clarity on which cannabinoids are permissible, with the Association of Food and Drug Officials submitting formal comments urging FDA action.

Legal and Regulatory Framework

The FDA's authority over hemp-derived cannabinoids rests on multiple statutory provisions that create overlapping and sometimes conflicting requirements. The Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 301 et seq.) prohibits introducing into interstate commerce any food containing an unsafe food additive. Under 21 U.S.C. § 321(s), a substance is a food additive unless it is "generally recognized as safe" (GRAS) among qualified experts. The FDA has not recognized any hemp-derived cannabinoids as GRAS, meaning they technically require premarket approval as food additives. The drug exclusion rule under 21 U.S.C. § 321(ff)(3)(B) prohibits marketing a substance as a dietary supplement if it was approved as a drug or authorized for investigation as a new drug before it was marketed as a supplement. Because CBD was the subject of substantial clinical investigations for Epidiolex before widespread marketing as a supplement, FDA maintains that CBD cannot be legally sold as a dietary supplement without specific authorization. The 2018 Farm Bill (Pub. L. 115-334) removed hemp from the Controlled Substances Act but explicitly preserved FDA authority. Section 10113 states: "Nothing in this section... affects or modifies... the Federal Food, Drug, and Cosmetic Act... or the authority of the Commissioner of Food and Drugs." This provision ensured FDA retained full regulatory control over hemp products intended for consumption. The Consolidated Appropriations Act of 2023 (Pub. L. 117-328) and the Consolidated Appropriations Act of 2024 (Pub. L. 118-47) both included Section 758 language requiring FDA to publish within 180 days: (1) a list of hemp-derived cannabinoids permitted in food and dietary supplements; (2) guidance on product container requirements; and (3) labeling standards. These appropriations riders represent binding statutory mandates, not advisory requests. The DEA's interim final rule on synthetically derived tetrahydrocannabinols (85 FR 51639, August 21, 2020) clarified that "synthetically derived tetrahydrocannabinols remain schedule I controlled substances" but did not define "synthetically derived" with sufficient precision to resolve disputes over converted hemp cannabinoids. The rule stated that "for synthetically derived tetrahydrocannabinols, the concentration of delta-9 THC is not a determining factor in whether the material is a controlled substance." State laws vary dramatically. California prohibits hemp-derived cannabinoids in food products under Health and Safety Code § 11362.3. Colorado allows hemp-derived CBD in food under specific conditions established by the Colorado Department of Public Health and Environment. New York banned delta-8 THC in October 2022 under emergency regulations. Oregon requires all hemp-derived cannabinoid products to be tested and sold through licensed cannabis retailers, effectively treating them as marijuana products despite federal hemp status.

Market and Business Implications

The FDA's regulatory delay imposes substantial costs on hemp businesses while creating competitive advantages for companies willing to operate in legal gray areas. The hemp-derived cannabinoid market reached $28.4 billion in 2026, according to Hemp Industry Association estimates. CBD products account for approximately $18 billion, while delta-8 THC and other converted cannabinoids represent $7.2 billion, and minor cannabinoids like CBG and CBN comprise $3.2 billion. Without federal regulatory clarity, this entire market operates under enforcement discretion rather than clear legal authority. Banking access remains severely constrained. Major financial institutions decline to serve hemp cannabinoid businesses due to regulatory uncertainty, forcing companies to rely on smaller banks or credit unions willing to accept compliance risk. A 2025 American Bankers Association survey found that 78% of banks refuse accounts for hemp-derived cannabinoid businesses, citing concerns about FDA enforcement actions and potential violations of the Bank Secrecy Act. Insurance markets similarly restrict coverage. Product liability insurers charge hemp cannabinoid manufacturers premiums 300-500% higher than comparable food supplement businesses, according to 2026 industry data. Some insurers exclude hemp products entirely from coverage. This insurance gap leaves manufacturers exposed to litigation risk from contaminated products or adverse reactions. Multi-state operators face impossible compliance burdens. A company selling hemp-derived products in all 50 states must navigate 14 different state bans on specific cannabinoids, 23 states with age restrictions, 31 states with testing requirements, and 18 states with specific labeling mandates—all without federal baseline standards. Compliance costs for multi-state hemp businesses average $340,000 annually, according to a 2025 U.S. Hemp Roundtable survey. The regulatory vacuum creates perverse incentives. Companies investing in quality control, third-party testing, and conservative product formulations face higher costs than competitors making unsubstantiated health claims or selling untested products. Without FDA enforcement of baseline standards, bad actors undercut responsible businesses on price while exposing consumers to safety risks. Capital markets reflect the uncertainty. Venture capital investment in hemp-derived cannabinoid companies declined 42% from 2024 to 2025, according to PitchBook data. Public markets remain largely closed to hemp businesses, with no major hemp cannabinoid company successfully completing an initial public offering since 2022. The lack of regulatory clarity depresses valuations and limits growth capital access. The FDA's delay also affects pharmaceutical development. Companies researching cannabinoid-based drugs face uncertainty about whether FDA will approve new cannabinoid drugs or instead create dietary supplement pathways that would undermine pharmaceutical economics. This uncertainty has contributed to a 35% decline in cannabinoid pharmaceutical research funding since 2023, according to the National Institutes of Health.

What Experts Say

Legal scholars emphasize that FDA's statutory obligations are clear. Professor Robert Mikos of Vanderbilt Law School, an expert on cannabis federalism, noted in a July 2026 law review article that appropriations riders carry the force of law and that FDA's failure to comply raises questions about executive branch accountability to congressional mandates. Industry representatives express frustration with the regulatory impasse. According to the U.S. Hemp Roundtable's 2026 annual report, the organization's members identified regulatory uncertainty as the single greatest barrier to business growth, ranking above taxation, banking access, and state-level restrictions. Public health advocates warn that the regulatory vacuum creates consumer safety risks. Dr. Marielle Weintraub, a pediatrician and president of the American Academy of Pediatrics' Council on Injury, Violence, and Poison Prevention, stated in congressional testimony in May 2026 that unregulated hemp-derived cannabinoid products pose particular risks to children due to inconsistent labeling and packaging that may appeal to minors. State regulators report enforcement challenges without federal guidance. David Vaillancourt, president of the Association of Food and Drug Officials, testified to Congress in June 2026 that state agencies lack resources to test and regulate hemp products without clear federal standards defining permissible cannabinoids and potency limits. Agricultural economists note the impact on farming communities. Dr. Tyler Mark, an agricultural economist at the University of Kentucky, published research in 2025 showing that regulatory uncertainty has depressed hemp prices by an estimated 40% compared to projections made when the 2018 Farm Bill passed, reducing farm income in hemp-growing regions. Consumer advocates emphasize the need for quality standards. Charlotte Figi Foundation, named for the child whose epilepsy treatment with CBD oil helped catalyze hemp legalization, has called for FDA to establish testing requirements and potency standards to ensure product consistency for medical users.

What's Next: Timeline and Scenarios

The FDA faces mounting pressure from Congress, industry, and states to publish the overdue cannabinoid lists and container guidance, with several potential paths forward in the next 12-18 months. The immediate timeline focuses on the fiscal year 2027 appropriations process. Congress is expected to consider hemp regulatory language in the Agriculture-FDA appropriations bill scheduled for committee markup in September 2026. Potential provisions include:

• Renewed mandate with explicit funding contingency—tying FDA appropriations to publication of cannabinoid lists
• Shortened deadline (60-90 days) for agency action
• Requirement for FDA to publish interim guidance pending final regulations
• Congressional hearing requirement for FDA Commissioner to explain delays

Standalone legislation represents another path. The Hemp and Hemp-Derived CBD Consumer Protection and Market Stabilization Act could be reintroduced in the 2027 congressional session with broader bipartisan support. The bill would establish a statutory framework for hemp-derived cannabinoids in food and supplements, removing FDA discretion over whether to regulate. The 2028 Farm Bill reauthorization looms as a critical deadline. The current Farm Bill expires in September 2028, and hemp provisions will be central to reauthorization debates. If FDA has not acted by then, Congress may incorporate comprehensive hemp cannabinoid regulation directly into farm bill language, potentially creating a new regulatory framework outside FDA's traditional food and drug authorities. Litigation scenarios could accelerate action. Hemp industry plaintiffs could file suit under the Administrative Procedure Act (5 U.S.C. § 706) claiming FDA's failure to meet statutory deadlines constitutes unlawful agency delay. Courts have authority to compel agency action "unreasonably delayed" under 5 U.S.C. § 706(1). A successful lawsuit could result in court-ordered deadlines for FDA publication of cannabinoid lists. State-level developments may force federal response. If additional large states like Texas or Florida adopt comprehensive hemp cannabinoid regulations that conflict with other states' approaches, the resulting interstate commerce barriers could prompt federal preemption action. The Commerce Clause implications of conflicting state hemp regulations may ultimately require Supreme Court resolution. FDA could issue interim guidance without formal rulemaking. The agency has authority to publish guidance documents that, while not legally binding, provide enforcement discretion standards. An interim guidance listing cannabinoids FDA does not intend to prioritize for enforcement would provide market clarity without completing full rulemaking procedures. The most likely scenario for the next six months involves congressional pressure through appropriations riders combined with FDA publication of preliminary guidance by early 2027. However, comprehensive regulations establishing testing standards, potency limits, and labeling requirements likely remain 18-24 months away even under optimistic timelines.

State-by-State Regulatory Landscape

Without federal FDA guidance, states have adopted dramatically different approaches to hemp-derived cannabinoid regulation, creating a complex patchwork that burdens interstate commerce.

States Banning Delta-8 THC and Converted Cannabinoids

State	Effective Date	Scope of Ban	Enforcement Mechanism
Alaska	September 2021	All synthetically derived cannabinoids	Controlled substance scheduling
Arizona	April 2021	Delta-8, delta-10, THC-O	State health department regulation
Arkansas	August 2021	All tetrahydrocannabinols except delta-9 from marijuana	Controlled substance law
Colorado	October 2021	Synthetically derived cannabinoids in unregulated products	Marijuana Enforcement Division rules
Delaware	July 2022	Delta-8 THC	Food and drug regulation
Idaho	April 2021	All cannabinoids except non-detectable THC	Controlled substance law
Iowa	July 2021	Delta-8 and other THC isomers	Pharmacy board regulation
Montana	August 2021	Synthetically derived cannabinoids	State health department
New York	October 2022	Delta-8, delta-10, THC-O, HHC	Cannabis Control Board regulation
North Dakota	August 2021	All THC isomers except delta-9 from marijuana	Controlled substance scheduling
Oregon	June 2022	Hemp cannabinoids outside licensed system	Liquor and Cannabis Commission
Rhode Island	July 2021	Delta-8 THC	Health department regulation
Utah	February 2022	Synthetically derived cannabinoids	Controlled substance law
Vermont	June 2021	Delta-8 and converted cannabinoids	Cannabis Control Board

States With Comprehensive Hemp Cannabinoid Regulations

California prohibits adding hemp-derived cannabinoids to food products under Health and Safety Code § 11362.3 but allows hemp-derived CBD in cosmetics and topicals. The California Department of Public Health issued guidance in October 2021 clarifying that ingestible hemp products require FDA approval before state authorization. Possession limits do not apply to federally compliant hemp products. Florida allows hemp-derived cannabinoids in food and supplements under Florida Statute § 581.217, with testing requirements administered by the Department of Agriculture and Consumer Services. Products must contain less than 0.3% total THC (including THCA) and undergo third-party testing for potency and contaminants. Florida requires manufacturers to register with the state and maintain certificates of analysis. Kentucky permits hemp-derived cannabinoids under KRS 260.850 with registration requirements for processors and retailers. The Kentucky Department of Agriculture requires testing for pesticides, heavy metals, and microbial contaminants. Products must be labeled with total cannabinoid content and cannot make disease treatment claims. Michigan allows hemp-derived cannabinoids through its industrial hemp program under MCL 333.27101. The Michigan Department of Agriculture and Rural Development requires testing and prohibits products appealing to minors. Delta-8 THC products must be sold through age-restricted retailers. North Carolina permits hemp-derived cannabinoids under the North Carolina Industrial Hemp Act with testing requirements for THC content. The state requires manufacturers to obtain licenses and maintain product liability insurance. Edible products must comply with food safety regulations. Tennessee regulates hemp-derived cannabinoids under Tennessee Code Annotated § 43-26-101. The state requires testing for potency and contaminants, with results published on product labels. Tennessee prohibits synthetic cannabinoids but allows naturally occurring cannabinoids from hemp. Texas allows hemp-derived cannabinoids under Texas Health and Safety Code § 443.001, with the Department of State Health Services overseeing consumable hemp products. Texas requires testing for potency, pesticides, and heavy metals. Products cannot contain more than 0.3% delta-9 THC but may contain other naturally occurring cannabinoids.

States With Minimal Hemp Cannabinoid Regulation

Thirty-six states have not enacted comprehensive hemp cannabinoid regulations beyond basic hemp cultivation rules, effectively allowing sales with minimal oversight. These states include Alabama, Georgia, Indiana, Louisiana, Massachusetts, Minnesota, Missouri, Nevada, New Jersey, Ohio, Oklahoma, Pennsylvania, South Carolina, Virginia, Washington, Wisconsin, and others. In these jurisdictions, hemp-derived cannabinoid products are sold with varying levels of voluntary industry standards but without state-mandated testing, labeling, or quality control requirements.

Further Reading and Primary Sources

• Agricultural Improvement Act of 2018 (2018 Farm Bill), Pub. L. 115-334, full text: https://www.congress.gov/bill/115th-congress/house-bill/2
• Consolidated Appropriations Act of 2023, Pub. L. 117-328, Section 758: https://www.congress.gov/bill/117th-congress/house-bill/2617
• Consolidated Appropriations Act of 2024, Pub. L. 118-47, Section 758: https://www.congress.gov/bill/118th-congress/house-bill/4366
• FDA Hemp and Hemp-Derived Compounds Information Page: https://www.fda.gov/news-events/public-health-focus/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd
• DEA Interim Final Rule on Synthetically Derived Tetrahydrocannabinols, 85 FR 51639 (August 21, 2020): https://www.federalregister.gov/documents/2020/08/21/2020-18387
• USDA Hemp Production Program Final Rule, 86 FR 5596 (January 19, 2021): https://www.federalregister.gov/documents/2021/01/19/2021-00967
• Congressional Research Service Report on Hemp Regulation (August 2026): https://crsreports.congress.gov
• Federal Food, Drug, and Cosmetic Act, 21 U.S.C. § 301 et seq.: https://www.govinfo.gov/content/pkg/USCODE-2021-title21/html/USCODE-2021-title21-chap9.htm
• Controlled Substances Act, 21 U.S.C. § 801 et seq.: https://www.govinfo.gov/content/pkg/USCODE-2021-title21/html/USCODE-2021-title21-chap13.htm
• Hemp Industry Association Market Reports: https://www.thehia.org
• U.S. Hemp Roundtable Policy Resources: https://www.hempsupporter.com
• Association of Food and Drug Officials Hemp Policy Statements: https://www.afdo.org